dengu
viru
infect
caus
hemorrhag
fever
shock
enceph
even
death
worldwid
approxim
billion
peopl
live
dengueinfest
region
million
new
case
year
although
mani
infect
believ
silent
four
antigen
distinct
serotyp
dengu
viru
thu
immun
one
serotyp
crossprotect
infect
three
difficulti
hamper
vaccin
develop
includ
requir
natur
conform
envelop
glycoprotein
induc
neutral
immun
respons
necess
present
antigen
four
serotyp
current
way
meet
requir
use
mixtur
four
serotyp
live
attenu
dengu
virus
safeti
remain
major
problem
studi
develop
basi
tetraval
dengu
vaccin
use
novel
complex
adenoviru
platform
capabl
express
multipl
antigen
de
novo
dengu
vaccin
construct
pair
vector
express
premembran
envelop
gene
two
differ
dengu
viru
serotyp
dengu
fever
widespread
mosquitoborn
ill
affect
estim
million
peopl
worldwid
year
major
dengu
viru
infect
asymptomat
go
unnot
diseas
occasion
present
symptom
sever
headach
retroorbit
pain
joint
muscl
pain
sever
case
lead
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
manifest
hemorrhag
multipl
organ
includ
central
nervou
system
well
massiv
vascular
damag
bleed
shock
fatal
rate
dhf
dss
reach
major
pediatr
demograph
dengu
virus
member
flaviviru
famili
virus
four
serotyp
dengu
viru
den
serotyp
ident
gene
structur
consist
three
structur
protein
capsid
c
premembran
prm
envelop
e
seven
nonstructur
protein
gene
translat
positivestrand
rna
genom
singl
polyprotein
cleav
individu
protein
cellular
viral
proteas
despit
structur
similar
variat
genet
sequenc
serotyp
mainli
membran
glycoprotein
prm
e
result
antigen
distinct
lack
cross
protect
among
serotyp
furthermor
subsequ
infect
altern
serotyp
may
enhanc
diseas
sever
contribut
onset
dhf
dss
one
possibl
diseas
enhanc
nonneutr
antibodi
may
aid
viral
entri
host
cell
therebi
enhanc
infect
altern
broadli
reactiv
cytotox
tlymphocyt
ctl
respons
den
antigen
absenc
neutral
respons
may
acceler
destruct
host
cell
current
licens
vaccin
avail
dengu
viru
infect
immun
enhanc
associ
subsequ
den
infect
success
den
vaccin
must
induc
neutral
respons
four
den
serotyp
simultan
tetraval
difficulti
hamper
vaccin
develop
includ
preserv
neutral
epitop
nativ
den
glycoprotein
antigen
necess
present
antigen
serotyp
dengu
vaccin
offer
tetraval
protect
vaccin
individu
would
suscept
develop
dhf
dss
infect
serotyp
target
vaccin
great
amount
effort
focus
tradit
approach
dengu
vaccin
develop
howev
approach
yet
gener
licens
tetraval
dengu
vaccin
exampl
live
attenu
den
vaccin
shown
protect
immun
anim
model
dengu
viru
infect
caus
hemorrhag
fever
shock
enceph
even
death
worldwid
approxim
billion
peopl
live
dengueinfest
region
million
new
case
year
although
mani
infect
believ
silent
four
antigen
distinct
serotyp
dengu
viru
thu
immun
one
serotyp
crossprotect
infect
three
difficulti
hamper
vaccin
develop
includ
requir
natur
conform
envelop
glycoprotein
induc
neutral
immun
respons
necess
present
antigen
four
serotyp
current
way
meet
requir
use
mixtur
four
serotyp
live
attenu
dengu
virus
safeti
remain
major
problem
studi
develop
basi
tetraval
dengu
vaccin
use
novel
complex
adenoviru
platform
capabl
express
multipl
antigen
dengu
fever
widespread
mosquitoborn
ill
affect
estim
million
peopl
worldwid
year
major
dengu
viru
infect
asymptomat
go
unnot
diseas
occasion
present
symptom
sever
headach
retroorbit
pain
joint
muscl
pain
sever
case
lead
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
manifest
hemorrhag
multipl
organ
includ
central
nervou
system
well
massiv
vascular
damag
bleed
shock
fatal
rate
dhf
dss
reach
major
pediatr
demograph
dengu
virus
member
flaviviru
famili
virus
four
serotyp
dengu
viru
den
serotyp
ident
gene
structur
consist
three
structur
protein
capsid
c
premembran
prm
envelop
e
seven
nonstructur
protein
gene
translat
positivestrand
rna
genom
singl
polyprotein
cleav
individu
protein
cellular
viral
proteas
despit
structur
similar
variat
genet
sequenc
serotyp
mainli
membran
glycoprotein
prm
e
result
antigen
distinct
lack
cross
protect
among
serotyp
furthermor
subsequ
infect
altern
serotyp
may
enhanc
diseas
sever
contribut
onset
dhf
dss
one
possibl
diseas
enhanc
nonneutr
antibodi
may
aid
viral
entri
host
cell
therebi
enhanc
infect
altern
broadli
reactiv
cytotox
tlymphocyt
ctl
respons
den
antigen
absenc
neutral
respons
may
acceler
destruct
host
cell
current
licens
vaccin
avail
dengu
viru
infect
immun
enhanc
associ
subsequ
den
infect
success
den
vaccin
must
induc
neutral
respons
four
den
serotyp
simultan
tetraval
difficulti
hamper
vaccin
develop
includ
preserv
neutral
epitop
nativ
den
glycoprotein
antigen
necess
present
antigen
serotyp
dengu
vaccin
offer
tetraval
protect
vaccin
individu
would
suscept
develop
dhf
dss
infect
serotyp
target
vaccin
great
amount
effort
focus
tradit
approach
dengu
vaccin
develop
howev
approach
yet
gener
licens
tetraval
dengu
vaccin
exampl
live
attenu
den
vaccin
shown
protect
immun
anim
model
unsuccess
human
due
underattenu
unbalanc
immun
serotyp
addit
sever
dengu
viru
chimera
vaccin
includ
yellow
feverdengu
viru
chimera
produc
protect
immun
respons
anim
concern
regard
potenti
side
effect
replicationcompet
hybrid
virus
howev
recent
clinic
trial
demonstr
monoval
yellow
feverdengu
viru
chimer
vaccin
well
toler
number
studi
shown
inject
dna
plasmid
contain
den
sequenc
immunogen
offer
protect
den
challeng
anim
model
approach
simpl
potenc
dna
vaccin
continu
major
limit
current
effort
focus
search
effect
adjuv
enhanc
immunogen
vaccin
anoth
encourag
platform
includ
use
replicationdefect
recombin
adenoviru
ad
vector
vaccin
vector
abil
express
antigen
high
level
wide
varieti
cell
type
make
ideal
induc
potent
immun
respons
addit
studi
vaccin
platform
wide
varieti
infecti
agent
includ
dengu
viru
tickborn
enceph
viru
human
immunodefici
viru
ebola
viru
marburg
viru
howev
major
limit
tradit
ad
vector
vaccin
approach
amount
antigen
inform
carri
singl
vector
specif
adbas
dengu
vaccin
fraction
e
gene
sequenc
singl
den
serotyp
express
vaccin
vector
present
report
introduc
dengu
vaccin
candid
base
pair
novel
complex
ad
vector
accommod
larg
antigen
sequenc
multipl
antigen
insert
assur
equal
express
antigen
four
serotyp
engin
prm
e
antigen
four
serotyp
den
symmetr
end
vector
genom
result
pair
vector
express
prm
e
glycoprotein
complex
four
den
serotyp
administ
togeth
vector
pair
would
repres
four
serotyp
prm
e
select
antigen
sever
epitop
within
den
e
protein
known
play
signific
role
induct
neutral
antibodi
nab
ctl
respons
express
flaviviru
prm
protein
necessari
proper
process
express
e
studi
tetraval
vaccin
test
singl
bival
compon
vector
abl
express
high
level
prm
e
protein
vitro
induc
potent
antibodi
four
den
serotyp
vivo
use
improv
plaqu
reduct
assay
show
antibodi
respons
inde
neutral
four
serotyp
presum
antigen
natur
express
associ
membran
final
de
novosynthes
antigen
induc
broadli
reactiv
cellular
immun
respons
respons
combin
neutral
immun
import
develop
protect
immun
four
serotyp
den
summari
data
demonstr
effici
induct
immun
respons
multipl
serotyp
dengu
virus
cadvaxbas
vaccin
support
investig
combin
two
compon
form
tetraval
adbas
dengu
vaccin
cell
line
virus
vero
cell
obtain
atcc
cell
line
maintain
dulbecco
modifi
eagl
medium
supplement
cosmic
calf
serum
cc
hyclon
penicillinstreptomycin
ps
cambrex
mous
splenocyt
cultur
rpmi
supplement
cc
mm
hepe
ps
nonessenti
amino
acid
hybridoma
cell
line
atcc
hybridoma
cell
line
obtain
us
armi
medic
research
institut
infecti
diseas
hybridoma
maintain
hybricar
medium
atcc
supplement
cc
ps
dengu
virus
hawaii
new
guinea
c
kindli
provid
barri
falgout
fda
center
biolog
evalu
research
construct
cadvaxd
vaccin
plasmid
contain
prme
gene
sequenc
four
dengu
viru
serotyp
kindli
provid
us
naval
medic
research
center
desir
gene
fragment
prme
pcr
amplifi
plasmid
use
primer
specif
serotyp
primer
sequenc
follow
genbank
access
number
forward
revers
gen
bank
access
number
forward
revers
genbank
access
number
forward
revers
genbank
access
number
forward
revers
prme
pcr
fragment
serotyp
gener
subclon
cadvax
arm
prme
sequenc
insert
left
right
arm
cadvaxd
vaccin
construct
respect
prme
sequenc
insert
left
right
arm
cadvaxd
vaccin
construct
respect
open
read
frame
sequenc
ensur
clone
dengu
viru
sequenc
correct
clone
construct
complet
cadvaxd
vaccin
vector
construct
describ
previous
immunoblot
analys
cell
infect
cadvaxd
cadvaxd
vector
multipl
infect
moi
h
cell
wash
three
time
phosphatebuff
salin
pb
lysat
prepar
use
mper
buffer
pierc
accord
manufactur
instruct
cell
lysat
l
separ
nupag
gel
invitrogen
transfer
polyvinyliden
difluorid
membran
membran
probe
antiden
monoclon
antibodi
mab
antibodi
use
specif
follow
us
naval
medic
research
center
hmaf
hyperimmun
mous
ascit
fluid
polyclon
protein
react
mab
visual
use
westernbreez
chemiluminesc
western
blot
immunodetect
kit
invitrogen
dengu
indirect
immunofluoresc
assay
vero
cell
mock
infect
infect
cadvaxd
vector
moi
wildtyp
dengu
virus
moi
two
day
postinfect
cell
fix
formaldehyd
block
permeabil
pb
nonfat
dri
milk
tween
triton
probe
serotypespecif
antiden
mab
mab
specif
e
e
e
e
prepar
undilut
supernat
hybridoma
cell
cultur
specif
mab
previous
describ
cell
probe
primari
antibodi
cell
wash
three
time
pb
contain
cc
probe
phycoerythrinconjug
antimous
immunoglobulin
g
secondari
antibodi
bd
pharmingen
cell
probe
secondari
antibodi
cell
wash
describ
visual
fluoresc
microscop
olympu
immun
mice
cadvaxd
vaccin
prepar
sera
mice
charl
river
laboratori
charleston
sc
immun
intraperiton
week
pfu
cadvaxd
cadvaxd
prepar
l
pb
unrel
cadvaxbas
sever
acut
respiratori
syndrom
hepat
b
viru
vaccin
respect
serv
neg
control
due
schedul
conflict
cadvaxd
group
actual
boost
day
prior
vol
adenovirusbas
multival
dengu
vaccin
week
collect
point
wherea
cadvaxd
group
anim
boost
day
collect
point
primari
vaccin
mice
blood
collect
biweekli
via
retroorbit
extract
light
anesthesia
co
inhal
serum
blood
sampl
prepar
previous
describ
small
aliquot
supplement
nan
store
anim
maintain
accord
institut
anim
care
use
committe
standard
regul
indirect
enzymelink
immunosorb
assay
elisa
vero
cell
cultur
supernat
coat
directli
onto
well
flatbottom
plate
nalg
nunc
intern
serv
coat
antigen
dengu
viru
serotyp
propag
vero
cell
approxim
day
cytopath
effect
evid
viru
prepar
collect
cell
cultur
supernat
store
titrat
perform
use
serotypespecif
mab
optim
amount
viru
prepar
use
coat
plate
optim
procedur
perform
viru
prepar
assay
perform
previous
describ
antibodi
titer
mous
determin
calcul
dilut
serum
correspond
signal
three
time
background
particular
test
den
prnt
ten
week
booster
immun
week
primari
immun
mice
describ
sacrif
blood
collect
via
cardiac
punctur
anim
sera
prepar
describ
perform
plaqu
reduct
neutral
test
prnt
analys
pfu
hawaii
new
guinea
c
incub
serial
dilut
heatinactiv
serum
vaccin
anim
follow
adsorpt
onto
vero
cell
plate
adsorpt
monolay
cover
agarmedium
overlay
agar
eagl
minimum
essenti
medium
cc
mm
lglutamin
nonessenti
amino
acid
mm
sodium
pyruv
ps
incub
day
infect
day
infect
co
infect
agar
overlay
remov
fix
block
accord
protocol
describ
indirect
immunofluoresc
fix
cell
probe
mab
clone
react
four
serotyp
den
antibodi
use
undilut
hybridoma
cell
cultur
supernat
cell
probe
primari
antibodi
wash
three
time
pb
contain
tween
probe
alkalin
phosphataseconjug
antimous
immunoglobulin
g
secondari
antibodi
kirkegaard
perri
cell
wash
three
time
plaqu
visual
ad
bcip
nitroblu
tetrazolium
substrat
pierc
viral
plaqu
count
raw
data
convert
percent
neutral
plaqu
format
murin
gamma
interferon
enzymelink
immunospot
elispot
assay
mice
vaccin
pfu
cadvaxd
cadvaxd
describ
four
mice
vaccin
group
sacrif
week
primari
immun
spleen
collect
previous
describ
splenocyt
isol
anim
dilut
concentr
cellsml
cultur
medium
antigen
stimul
pool
consecut
peptid
span
amino
acid
envelop
protein
use
synthes
mimitop
victoria
australia
peptid
pool
consist
total
peptid
overlap
peptid
individu
dissolv
dimethyl
sulfoxid
approxim
mgml
peptid
pool
gener
combin
overlap
peptid
final
concentr
gml
multiscreen
assay
plate
millipor
coat
rat
antimous
captur
antibodi
bd
pharmingen
incub
overnight
next
day
plate
wash
three
time
pb
block
lwell
cultur
medium
hour
room
temperatur
next
dengu
viru
peptid
pool
mixtur
ad
well
l
per
well
follow
equal
volum
splenocyt
suspens
cellsml
plate
incub
h
elispot
assay
complet
previous
describ
four
serotyp
dengu
viru
structur
ident
fig
engin
cadvax
vector
express
prm
e
gene
two
differ
dengu
viru
serotyp
fig
c
prme
cassett
insert
left
right
cadvax
arm
cassett
insert
left
right
arm
respect
cadvaxd
fig
cassett
insert
left
right
arm
respect
cadvaxd
fig
bival
vector
construct
propag
purifi
titrat
previous
describ
method
cadvax
dengu
vector
express
high
level
dengu
viru
protein
vitro
follow
construct
two
bival
vector
confirm
express
correct
dengu
viru
antigen
use
western
blot
analysi
cell
lysat
infect
either
cadvaxd
cadvaxd
found
cadvaxd
induc
prm
express
vitro
fig
lane
respect
seri
western
blot
also
confirm
e
express
fig
lane
respect
also
detect
e
protein
cadvaxd
infect
cell
lysat
fig
lane
respect
unfortun
unabl
detect
prm
protein
express
serotyp
due
lack
serotypespecif
antibodi
protein
howev
express
e
protein
may
provid
indirect
evid
prm
protein
serotyp
also
express
prme
cassett
cadvaxd
vector
design
express
singl
polyprotein
upon
infect
target
cell
therefor
detect
e
distal
prm
cadvaxd
infect
cell
lysat
indirectli
indic
prm
protein
serotyp
also
express
furthermor
e
protein
appear
approxim
molecular
mass
kda
e
protein
fig
previou
work
relat
flavivirus
shown
prm
pro
therefor
appear
e
protein
molecular
mass
similar
e
protein
also
indirect
evid
prm
prm
present
cadvaxd
infect
cell
confirm
result
western
blot
analys
perform
indirect
immunofluoresc
assay
use
serotypespecif
monoclon
antibodi
shown
fig
cadvaxd
vector
demonstr
posit
stain
especif
mab
especif
mab
mab
distinguish
e
e
posit
stain
control
suggest
mab
abl
demonstr
e
express
addit
lack
stain
lysat
confirm
mab
specif
similar
result
seen
cadvaxd
cadvaxd
also
demonstr
posit
express
respect
gene
insert
fig
cadvaxd
infect
cell
posit
stain
especif
mab
especif
mab
specif
bind
cell
confirm
specif
mab
addit
negativecontrol
mockinfect
cell
show
detect
background
nonspecif
bind
collect
data
indic
e
protein
four
den
serotyp
express
cadvaxd
vector
support
western
blot
fig
lack
crossreact
among
serotyp
confirm
specif
natur
mab
use
experi
consist
initi
introduct
character
vaccin
mice
cadvaxd
vector
induc
humor
immun
respons
mice
vaccin
describ
legend
fig
vaccin
unrel
cadvaxbas
sever
acut
respiratori
syndrom
hepat
b
viru
vaccin
respect
serv
neg
control
sera
vaccin
mice
collect
use
perform
elisa
detect
dengu
virusreact
antibodi
describ
materi
method
found
anim
vaccin
cadvaxd
produc
high
titer
antibodi
detect
earli
week
primari
immun
fig
titer
decreas
slightli
week
show
rebound
effect
week
like
result
booster
immun
day
prior
time
point
interestingli
found
almost
ident
result
measur
antibodi
titer
mice
fig
consid
sera
serotyp
crossreact
antigen
express
cadvaxd
vaccin
vector
anim
vaccin
cadvaxd
produc
high
titer
antibodi
fig
evid
booster
immun
demonstr
increas
titer
week
describ
found
sera
anim
also
react
strongli
dengu
viru
serotyp
cover
vaccin
vector
ie
fig
sera
control
anim
show
reactiv
either
dengu
viru
serotyp
result
indic
cadvaxd
vaccin
induc
product
antibodi
crossreact
dengu
viru
serotyp
contain
within
respect
vector
howev
antibodi
still
specif
den
control
vaccin
induc
denreact
antibodi
product
addit
antibodi
respons
long
last
cadvaxdvaccin
mice
antiden
antibodi
titer
remain
elev
averag
titer
log
scale
week
primari
vaccin
data
shown
vaccin
induc
tetraval
neutral
antibodi
next
measur
neutral
antibodi
respons
mice
vaccin
describ
use
plaqu
reduct
neutral
test
found
nab
respons
show
slightli
serotypespecif
profil
crossreact
antibodi
detect
elisa
describ
exampl
neutral
activ
serotyp
higher
sera
cadvaxd
vaccin
anim
sera
cadvaxd
vaccin
anim
fig
b
found
invers
relationship
examin
nab
respons
serotyp
sera
anim
vaccin
cadvaxd
effect
neutral
sera
anim
vaccin
cadvaxd
fig
differ
serotyp
specif
rel
small
high
level
serotyp
crossneutr
induc
dengu
vaccin
group
cadvaxd
anim
sera
show
much
higher
level
neutral
antibodi
activ
four
den
serotyp
compar
controlvaccin
anim
sera
serotypeindepend
cellular
immun
respons
mice
vaccin
cadvaxd
vector
detect
cellular
immun
respons
induc
vaccin
candid
mice
vaccin
intraperiton
pfu
cadvaxd
cadvaxd
week
group
mice
sacrif
week
primari
immun
measur
ctl
activ
group
cadvaxdvaccin
mice
much
higher
ctl
activ
control
group
fig
evid
week
primari
immun
addit
ctl
profil
cadvaxd
vaccin
anim
similar
cadvaxd
vaccin
anim
even
though
antigen
stimul
assay
deriv
e
protein
may
indic
serotyp
crossreact
ctl
respons
increas
ctl
activ
detect
three
vaccin
group
week
primari
immun
whether
due
booster
immun
week
simpli
timedepend
phenomenon
unknown
data
conclud
addit
humor
immun
respons
cadvaxd
vaccin
also
induc
cellular
immun
respons
dengu
viru
protein
vaccin
mice
cellular
respons
potenti
broadli
reactiv
across
serotyp
one
prerequisit
tetraval
dengu
vaccin
must
induc
direct
neutral
immun
respons
four
serotyp
crossreact
nonneutr
antibodi
respons
prevent
dengu
viru
infect
even
implic
major
caus
factor
immun
enhanc
diseas
present
two
major
obstacl
first
neutral
target
antigen
prm
e
must
natur
conform
present
receptor
bind
site
neutral
epitop
resid
protein
antigen
synthes
nonmammalian
cell
cultur
fulli
glycosyl
fold
differ
even
antigen
produc
mammalian
cell
denatur
purif
process
therefor
antigen
often
induc
strong
neutral
respons
second
requir
present
antigen
four
serotyp
dengu
virus
similar
ratio
prevent
underrepresent
one
four
serotyp
particularli
difficult
achiev
even
live
attenu
viru
vaccin
viru
attenu
differ
furthermor
attenu
viru
may
behav
differ
differ
peopl
popul
overattenu
may
caus
subtyp
underrepres
caus
immun
enhanc
underattenu
caus
infect
individu
vaccin
seen
recent
halt
phase
iii
clinic
trial
current
studi
present
novel
dengu
vaccin
strategi
induc
multival
immun
respons
de
novo
synthesi
antigen
four
serotyp
viru
present
report
first
describ
complex
ad
vector
system
capabl
express
multipl
dengu
viru
prm
e
antigen
singl
vector
possibl
induc
tetraval
immun
respons
anim
model
use
combin
cadvax
system
capabl
accommod
larg
amount
foreign
antigen
sequenc
multipl
antigen
insert
allow
induc
balanc
express
neutral
antigen
four
serotyp
viru
assur
prm
e
antigen
express
similarli
high
level
put
prm
e
serotyp
ident
immediateearli
cytomegaloviru
cmvbovin
growth
hormon
polyadenyl
cassett
insert
express
cassett
either
end
cadvax
vector
potent
cytomegaloviru
promot
bovin
growth
hormon
polyadenyl
sequenc
provid
high
level
antigen
express
near
symmetr
insert
cassett
end
adenoviru
genom
provid
express
cassett
similar
flank
environ
assur
similar
level
express
inde
result
show
similar
level
express
prm
e
protein
importantli
similar
level
neutral
immun
respons
serotyp
dengu
viru
vaccin
anim
immun
respons
induc
cell
express
dengu
viru
antigen
surfac
mimick
dengu
virusinfect
cell
immun
system
contrast
protein
subunitbas
vaccin
de
novosynthes
antigen
natur
form
glycosyl
shown
diffus
band
western
blot
associ
cell
membran
recogn
immunostain
provid
persist
immun
system
stimul
induc
potent
humor
cellular
respons
furthermor
antibodi
produc
neutral
four
serotyp
presum
natur
form
membran
glycoprotein
intact
receptor
bind
site
contain
neutral
epitop
antigen
synthes
dengu
viru
gene
transfer
cell
antigen
synthesi
may
last
week
provid
potent
continu
stimul
immun
system
induc
ctl
respons
shown
elispot
assay
ctl
respons
broadli
reactiv
four
serotyp
import
elimin
dengu
viru
infect
presenc
neutral
immun
respons
howev
basi
epidemiolog
studi
broadli
reactiv
ctl
respons
alon
suffici
prevent
dengu
viru
infect
differ
serotyp
may
contribut
enhanc
diseas
due
massiv
number
host
cell
infect
viru
absenc
neutral
antibodi
underlin
import
induc
balanc
neutral
immun
respons
four
serotyp
dengu
viru
previou
studi
describ
adbas
dengu
vaccin
vector
express
ectodomain
e
protein
vector
induc
neutral
antibodi
respons
mice
howev
serotyp
test
comparison
experiment
result
fig
vaccin
mice
cadvaxd
vector
induc
antidengu
viru
cellular
immun
respons
mice
vaccin
pfu
cadvaxd
cadvaxd
anim
sacrif
week
primari
immun
isol
splenocyt
anim
incub
pool
overlap
peptid
deriv
e
protein
amino
acid
incub
antimous
elispot
assay
perform
detect
denspecif
ctl
activ
result
present
number
spot
form
per
cell
data
point
repres
mean
plu
standard
deviat
error
bar
four
individu
anim
vol
adenovirusbas
multival
dengu
vaccin
march
guest
http
cviasmorg
aforement
studi
studi
difficult
due
differ
vector
design
vaccin
schedul
serum
collect
time
point
mous
strain
common
critic
ad
vector
use
human
possibl
preexist
immun
adenoviru
particular
adenoviru
subtyp
adenoviru
subtyp
common
subtyp
use
vectorbas
gene
therapi
vaccin
studi
also
one
subtyp
vast
major
world
alreadi
immun
presenc
circul
ad
neutral
antibodi
potenti
limit
adbas
vector
vaccin
efficaci
howev
recent
clinic
trial
found
correl
preexist
adneutr
antibodi
titer
potenc
adbas
influenza
vaccin
human
support
data
mercknih
vaccin
research
center
phase
iii
human
immunodefici
viru
vaccin
trial
conclud
use
highli
immunogen
antigen
combin
higher
dose
suffici
overcom
preexist
immun
furthermor
previou
studi
cadvaxbas
vaccin
indic
subsequ
booster
vaccin
hinder
primari
immun
fact
booster
vaccin
actual
enhanc
immun
respons
target
antigen
anim
model
also
support
data
present
cadvaxd
vaccin
vector
summari
present
two
cadvax
dengu
vaccin
vector
individu
function
bival
dengu
viru
vaccin
candid
mous
model
vaccin
addit
data
present
indic
two
vector
potenti
creat
tetraval
dengu
viru
vaccin
candid
administ
combin
studi
progress
test
bival
vector
anim
challeng
model
individu
twocompon
tetraval
mixtur
result
studi
provid
valuabl
insight
potenti
vaccin
induc
tetraval
antidengu
viru
immun
respons
actual
protect
dengu
viru
infect
anim
model
